- Time of issue:2021-09-01 15:43:30
EGF vaccine (rEGF-p64K/Mont vaccine) is a chemically coupled peptide vaccine jointly developed by Biotech Biopharmaceutical Co., Ltd. and Cuba. The product abbreviation is hu-rEGF-rP64k/Mont vaccine, which is a conjugate of the following two substances: 1. Recombinant human epidermal growth factor (hu-rEGF) produced in Saccharomyces cerevisiae; 2. Recombinant produced in Escherichia coli Neisseria meningitidis P64k protein. The two purified proteins were coupled with glutaraldehyde and purified by ultrafiltration. The conjugate is filled into a vial according to the final dosage form of the hu-rEGF-rP64k/Mont vaccine. The vaccine was mixed into an emulsion with the mineral oil adjuvant Montanide ISA 51 VG (SEPPIC, France) during injection.
The vaccine blocks EGFR-mediated cell signal transduction through specific active immunity, thereby inhibiting the growth of tumor cells and nourishing blood vessels, and causing tumor cell apoptosis (programmed death), thereby achieving the effects of tumor suppression and cancer treatment , Improve the patient's survival rate and quality of life. Animal experiments and clinical studies have shown that the vaccine has a good effect on malignant tumors with over-expression of epidermal growth factor receptor (EGFR), including lung cancer, head and neck cancer, and ovarian cancer, especially for non-small cell lung cancer.
At present, it has been approved for marketing in Cuba, Peru, and Paraguay for the treatment of advanced non-small cell lung cancer. Phase I clinical studies in patients with advanced non-small cell lung cancer in China have also ended, and phase II/III clinical studies are being planned.